Local woman heads to Mexico – News – seacoastonline.com … – Seacoastonline.com
By Dr. Matthew Watson
By Suzanne Laurentnews@seacoastonline.com
NEWMARKET Karen Olivier is excitedly looking forward to what she calls her stem cell birthday.
Olivier, 40, is traveling April 23 to Monterrey, Mexico, to undergo a procedure that will reset her immune system and stop the inflammation in her body, caused by her relapsing-remitting multiple sclerosis.
Diagnosed with MS at the age of 24, Olivier learned about a treatment called hematopoietic stem cell therapy, or HSCT, from a Facebook page. It gave her hope that if she had this treatment, it would stop the progression of the disease.
She began blogging about her journey leading up to her trip to Mexico.
I want others to know this is an option, she said.
According to the National Multiple Sclerosis Society, HSCT attempts to reboot the immune system, which is responsible for damaging the brain and spinal cord in MS. In HSCT, hematopoietic (blood cell-producing) stem cells are derived from the persons own bone marrow or blood, are collected and stored, and the rest of the individuals immune cells are depleted by chemotherapy.
The stored hematopoietic stem cells are then reintroduced to the body. The new stem cells migrate to the bone marrow and, over time, produce new white blood cells. Eventually they repopulate the body with immune cells, building a new immune system that doesnt know what MS is.
In early clinical trials, 78 percent of participants experienced no new disease activity after the procedure and did not need disease-modifying therapies to control their disease.
Olivier had been taking disease modifying drugs, or DMDs, for 15 years, starting with Avonex, a once weekly intramuscular injection. She then took Rebif, a subcutaneous injection three times a week. After she took a daily injection of Copaxone. In 2009, she started on Tysabri, receiving an infusion every 28 days.
I did well on the Tysabri, but in the past couple of years, my symptoms progressed and my most recent MRI showed new disease activity on my thoracic spine, Olivier said. At the rate my MS was progressing, I would probably be in a wheelchair in two years.
Since 1993, the Federal Drug Administration has approved DMDs to treat relapsing-remitting MS. All are designed to suppress the immune system to one degree or another. These drugs cost about $5,000 per month and they must be taken indefinitely, since relapses will occur if the drugs are stopped.
Oliviers insurance covered the cost of the drugs, but her copays and coinsurance amounts were still very high, she said. One month of a DMD infusion can cost between $7,000 and $9,000.
Olivier researched a clinical trial of HSCT in Chicago, a program begun in 1996 by Dr. Richard Burt, now chief of the division of medicine-immunology and autoimmune diseases at Northwestern Universitys Feinberg School of Medicine.
Trial criteria included relapsing-remitting MS, and failure on at least two DMDs and two flare-ups in the past 12 months, requiring treatment from steroids, she said.
In the United States, HSCT can cost between $150,000 and $200,000.
Insurance may have covered it out-of-network, but my plan has a substantial out-of-pocket maximum, Olivier said. It would have require multiple trips to Chicago for several years, and I could have ended up in the control group.
Olivier began to explore receiving HSCT in other countries and decided to apply for the treatment at Clinica Ruiz in Mexico last October when she was recovering from a flare-up. Clinica Ruiz is based in Pueblo, Mexico, but has expanded to a second clinic in Monterrey.
She and her husband, Jason, agreed spend the $54,500 out-of-pocket cost for the outpatient treatment that also includes transportation to and from a two-bedroom apartment where she will stay for 28 days. Her mother is traveling with her, as the treatment protocol requires the patient to have a caregiver present.
I was accepted based on my MS history and my expanded disability status scale (EDSS) score that basically measures how mobile you are, Olivier said.
Olivier will undergo two days of chemotherapy to wipe out her immune system. She will then have seven days of injections to promote stem cell growth, after which stem cells will be harvested from her blood.
Ill then have two more days of chemotherapy, she said. Im excited. No chemo, no cure.
May 7 will be what Olivier calls her stem cell birthday when she receives her stem cells back to reboot her immune system. She will then be in isolation in the apartment for about a week. Her mother will have to wear special precaution gear during that time.
Some people see improvements in the first three months, with full recovery in two years, Olivier said. Some might say Im not sick enough for this treatment, but the earlier someone gets it, the better, before the MS causes major damage.
She added that some people believe this is a risky procedure and it has not been FDA-approved yet in the United States.
But many people have died on Tysabri and the drug approved by the FDA last week, Ocrevus, has an increased risk of cancer after two to three years. I am hoping the HSCT will stop the progression of my MS, and hope that I never have to go on another DMD in my life.
To read Oliviers blog, visit knockoutmsblog.wordpress.com.
Read the rest here:
Local woman heads to Mexico - News - seacoastonline.com ... - Seacoastonline.com
- Efficacy and safety of human umbilical cord-derived mesenchymal stem cells in the treatment of refractory immune ... - Nature.com - April 28th, 2024
- Stem Cell Therapy: Know How The Procedure Stops Cancer - Times Now - April 28th, 2024
- Rejuvenating the immune system by depleting certain stem cells - National Institutes of Health (NIH) (.gov) - April 19th, 2024
- New gene therapy eliminates need for bone marrow transplant. Here's how it works. - CBS News - April 19th, 2024
- New gene therapy eliminates need for bone marrow transplant. Here's how it works. - MSN - April 19th, 2024
- Long Island boy with rare blood disorder undergoes gene therapy - MSN - April 19th, 2024
- Philadelphia Wings player, Connecticut man will be forever bonded by bone marrow donation: "He's my hero" - CBS Philly - April 10th, 2024
- VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide ... - Nature.com - April 10th, 2024
- Register as a bone marrow donor today and save lives - The Citizen - April 10th, 2024
- Resilient anatomy and local plasticity of naive and stress haematopoiesis - Nature.com - March 26th, 2024
- A Deeper Depth of Response After Salvage Therapy Improves Outcomes of Autologous Stem Cell Transplantation in ... - Cureus - March 26th, 2024
- Iron restriction keeps blood stem cells young, researchers find - Phys.org - March 18th, 2024
- Blood drive, bone marrow testing to be held in local woman's memory - The Winchester Star - March 18th, 2024
- Signal of Benefit for Stem Cell Therapy in Progressive MS - Medscape - March 10th, 2024
- Woman, 22, With Leukemia Recalls Symptoms And New Treatment She Received: EXCLUSIVE - TODAY - March 10th, 2024
- This Swedish startup wants to reduce the cost, and controversy, around stem cell production - TechCrunch - March 10th, 2024
- Outcomes and prognosis of haploidentical haematopoietic stem cell transplantation in children with FLT3-ITD mutated ... - Nature.com - March 10th, 2024
- Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor ... - Nature.com - March 10th, 2024
- Hematopoietic cell transplantation and cell therapy activity landscape survey in the Kingdom of Saudi Arabia; a report ... - Nature.com - March 10th, 2024
- How an MS friendship led to HSCT and a love of running - Multiple Sclerosis News Today - March 10th, 2024
- Iron Limitation Preserves Youthfulness of Blood Stem Cells - Mirage News - March 10th, 2024
- Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the ... - Nature.com - March 10th, 2024
- AJMC in the Press, February 23, 2024 - AJMC.com Managed Markets Network - February 24th, 2024
- Orca Bio Presents Promising Data on Orca-T in Two Oral Presentations at the 2024 Tandem Meetings of ASTCT and ... - Yahoo Finance - February 24th, 2024
- New approaches to live-track the production of different types of blood cells in mice - Medical Xpress - February 24th, 2024
- If Other Treatments Aren't Working -- Stem Cell Transplant May Be A Good Option In CLL - SurvivorNet - February 24th, 2024
- Expanding the Horizons of Cell and Gene Therapy - RegMedNet - February 24th, 2024
- The strangers who saved each others lives - BBC - February 24th, 2024
- City of Hope Research Featuring the Successful Treatment of the Oldest Patient to Achieve Remission for Leukemia ... - StreetInsider.com - February 15th, 2024
- 3D printing and material processing combined to create artificial bone - Optics.org - February 15th, 2024
- Man, 63, is in remission from HIV five years after receiving groundbreaking stem cell transplant... - The Sun - February 15th, 2024
- Team demonstrates fabrication method to construct 3D structures that mimic bone microstructure - Phys.org - February 15th, 2024
- Hematopoietic Stem Cells and Their Role in Development and Disease Therapy - The Scientist - February 15th, 2024
- Blood cell family trees trace how production changes with aging - MIT News - February 7th, 2024
- New study on promising stem cell-based therapy for Crohn's disease - Medical Xpress - January 30th, 2024
- Second haploidentical bone marrow transplantation with antithymocyte antibody-containing conditioning regimen for ... - Nature.com - January 30th, 2024
- Stem cell study shows how gene activity modulates the amount of immune cell production in mice - Medical Xpress - January 30th, 2024
- Global Stem Cell Therapy Industry Outlook to 2028, Driven by Therapeutic Innovations and Clinical Advancements ... - Yahoo Finance - January 30th, 2024
- 1st-of-its-kind therapy blocks immune attack after stem-cell transplant - Livescience.com - January 22nd, 2024
- Individualized dose of anti-thymocyte globulin based on weight and pre-transplantation lymphocyte counts in pediatric ... - Nature.com - January 22nd, 2024
- Implications of stress-induced gene expression for hematopoietic stem cell aging studies - Nature.com - January 22nd, 2024
- LVHN announces opening of new stem cell transplant center. Here's what that means for the Lehigh Valley - The Morning Call - January 22nd, 2024
- Fast Five Quiz: Chronic GVHD Risk Factors and Prevention - Medscape Reference - January 22nd, 2024
- Could Treatments for HIV and Sickle Cell Open the Gene Therapy Floodgates? - BioSpace - January 22nd, 2024
- Effects of fine particulate matter on bone marrow-conserved hematopoietic and mesenchymal stem cells: a systematic ... - Nature.com - January 14th, 2024
- Donating Bone Marrow and Stem Cells: The Process and What To Expect - On Cancer - Memorial Sloan Kettering - January 14th, 2024
- No, Rep. Steve Scalise Didn't Vote Against Stem Cell Research From Which He Is Now Benefiting - Yahoo News - January 14th, 2024
- Hematopoietic Stem Cell Transplantation Market to Grow Rapidly During the Study Period (2019-2032), Evaluates ... - PR Newswire - January 14th, 2024
- Life-saving donation from Philly athlete saves life: 'Feeling so strong, I owe that all to him' - AOL - January 14th, 2024
- The Key to Creating Blood Stem Cells May Lie in Your Own Blood - ScienceAlert - January 14th, 2024
- Dr Phillips on the Rationale for the GLOBRYTE Trial in Relapsed/Refractory MCL - OncLive - January 14th, 2024
- COVID-19 and HSCT Recipients: Risk Factors and Prevention Measures - Medriva - January 14th, 2024
- Bone Marrow Transplant: Heres What You Need To Know About This Therapy - Times Now - January 5th, 2024
- New insights about the development of hematopoietic stem cells - Drug Target Review - December 28th, 2023
- Bone Marrow Transplantation | Johns Hopkins Medicine - December 20th, 2023
- Stem Cell or Bone Marrow Transplant | American Cancer Society - December 20th, 2023
- Embryonic-stem-cell-derived mesenchymal stem cells relieve experimental contact urticaria by regulating the functions ... - Nature.com - December 20th, 2023
- Researchers discover crucial step in creating blood stem cells - Phys.org - December 20th, 2023
- A niche topic: understanding the development of hematopoietic stem cells - Fred Hutchinson Cancer Center - December 20th, 2023
- Vertex developed a CRISPR cure. Its already on the hunt for something better. - MIT Technology Review - December 20th, 2023
- FDA approves cure for sickle cell disease, the first treatment to use gene-editing tool CRISPR - NBC News - December 12th, 2023
- First therapy using CRISPR technology will treat sickle cell disease - Morning Brew - December 12th, 2023
- 7 medical breakthroughs that gave us hope in 2023 - National Geographic - December 12th, 2023
- Understanding Chronic Myeloid Leukemia: Causes, Symptoms, and Treatment - Everyday Health - December 12th, 2023
- Mansour bin Zayed witnesses inauguration of ADSCC Bone Marrow Transplant & Cellular Therapy Congress 2023 - ZAWYA - November 26th, 2023
- ADSCC Bone Marrow Transplant and Cellular Therapy Congress 2023 to take place in Abu Dhabi - ZAWYA - November 18th, 2023
- Orchard Therapeutics Reports First Quarter 2023 Financial Results and Announces Initiation of Rolling Submission for Biologics License Application of... - May 16th, 2023
- Family of 7-month-old in need of bone marrow transplant hosting donor registration event - CBS Pittsburgh - May 8th, 2023
- Anika Continues to Expand Addressable Market for Tactoset Injectable Bone Substitute with Additional 510(k) Clearance from FDA - Marketscreener.com - April 5th, 2023
- MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023 -... - April 5th, 2023
- VOR BIOPHARMA INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K) - Marketscreener.com - March 25th, 2023
- BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100 - Marketscreener.com - March 17th, 2023
- BioSenic delivers a new post-hoc analysis of its Phase III JTA-004 trial on knee osteo-arthritis with positive action on the most severely affected... - March 17th, 2023
- JASPER THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.com - March 9th, 2023
- For a range of unmet medical needs, India offers a fantastic opportunity to push cell and gene therapies: B .. - ETHealthWorld - March 9th, 2023
- NGM BIOPHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K) - Marketscreener.com - March 1st, 2023
- Bone health: Tips to keep your bones healthy - Mayo Clinic - January 27th, 2023
- Bone marrow drive held for military wife with cancer - January 27th, 2023
- Bone cancer - Symptoms and causes - Mayo Clinic - January 27th, 2023
- Bone | Definition, Anatomy, & Composition | Britannica - January 19th, 2023